Clinical trial results showed that 23 MF patients who received ruxolitinib treatment had varying degrees of decreased levels of plasma inflammatory factors IL-6, TNF-α, MIP-lB, and IL-1R.27Highly investigated markers of inflammation in MPN include high-sensitivity CRP (hs-CRP) and pentraxin-3 (PTX-3). Here, IL6 is linked to myeloproliferative neoplasm.